PROFOUND MEDICAL CORP. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
PROFOUND MEDICAL CORP. (PROF) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -2.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-05
- PROFOUND MEDICAL CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -2.60%.
- PROFOUND MEDICAL CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.70%.
- PROFOUND MEDICAL CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -1.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -2.60% 10-K · filed 2026-03-05 |
| 2024-12-31 | -0.70% 10-K · filed 2026-03-05 |
| 2023-12-31 | -1.60% 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |